Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

2.540 -0.040 (-1.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022
SAN FRANCISCO, CA / ACCESSWIRE / April 20, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / April 15, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA Veterinary... 
From Jaguar Health, Inc.
Via AccessWire
Why Is Jaguar Health (JAGX) Stock Up Today?
Here's the big partnership news that's taking shares of Jaguar Health and JAGX stock soaring in afternoon trading today. 
Via InvestorPlace
Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer
Dr. Chaturvedi continues to serve as Chair of company's Scientific Advisory Board Dr. Chaturvedi continues to provide leadership to the development of two crofelemer pipeline indications, with... 
From Jaguar Health, Inc.
Via AccessWire
Here's Why Jaguar Health Shares Are Rising
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 10.90% at $0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing... 
Via Benzinga
Here's Why Jaguar Health Shares Are Popping Off
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 31.2% at $0.70 after the company announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and... 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Rise and shine, trader! We're getting ready for another busy day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human... 
From Jaguar Health, Inc.
Via AccessWire
80 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 114.0% to $0.59 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of... 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie... 
Via Benzinga
Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast
Click here to access webcast replay Core 2022 development initiatives: - Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea... 
From Jaguar Health, Inc.
Via AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back! I hope you're recharged from the weekend break because we've got the biggest pre-market stock movers to start Monday with! 
Via InvestorPlace
Jaguar Health Provides Company Updates and Reports 2021 Financials
Core 2022 development initiatives: - Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) - Initiation and completion in... 
From Jaguar Health, Inc.
Via AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CVRx (NASDAQ:CVRX) shares rose 11.6% to $7.2 during Friday's after-market session. The market value of their outstanding shares is at $156.2 million. 
Via Benzinga
Jaguar Health's Earnings: A Preview
Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates
Click here to register for webcast Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021 SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 /... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA U.S. veterinarians,... 
From Jaguar Health, Inc.
Via AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Surgalign Holdings (NASDAQ:SRGA) ... 
Via Benzinga
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business model SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX),... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)
Study results expected to be described in upcoming presentations and publications CDD patients face intestinal failure (IF), similar to patients suffering from short bowel syndrome (SBS) - the priority... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has... 
From Jaguar Health, Inc.
Via AccessWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Stealth BioTherapeutics (NASDAQ:MITO 
Via Benzinga
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure... 
From Jaguar Health, Inc.
Via AccessWire
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS